Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
https://www.nature.com/articles/s41574-020-0392-2.pdf
Reference253 articles.
1. Tancredi, M. et al. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 373, 1720–1732 (2015).
2. Bommer, C. et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 5, 423–430 (2017).
3. Scheen, A. J. & Charbonnel, B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. Diabetes Metab. 40, 176–185 (2014).
4. Kirkman, M. S., Mahmud, H. & Korytkowski, M. T. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes mellitus. Endocrinol. Metab. Clin. North. Am. 47, 81–96 (2018).
5. Lipska, K. J. et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. Diabetes Care 40, 468–475 (2017).
Cited by 194 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sodium–glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective;The Lancet Diabetes & Endocrinology;2024-09
2. Dapagliflozin: A sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling;European Journal of Pharmacology;2024-09
3. Laboratory Aspects of Using the Results of NT-Probnp Concentration Immunochemical Determination in the Management of Patients With Heart Failure: Support For Clinical Decision-Making;Kardiologiia;2024-08-31
4. APOB and CCL17 as mediators in the protective effect of SGLT2 inhibition against myocardial infarction: Insights from proteome-wide mendelian randomization;European Journal of Pharmacology;2024-08
5. Dapagliflozin improves skeletal muscle insulin sensitivity through SIRT1 activation induced by nutrient deprivation state;Scientific Reports;2024-07-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3